Nature Medicine
2026-06-22 00:00
DOI:
HASH:4a0c8a3d0b8d2098e971b538acadc7a0
<b>PROTEUS trial heralds perioperative therapy for prostate cancer</b>
Authors:
Abstract
Perioperative androgen-deprivation therapy plus apalutamide could represent a new treatment option for patients with high-risk, localized prostate cancer. Perioperative androgen-deprivation therapy plus apalutamide could represent a new treatment option for patients with high-risk, localized prostate cancer.